Experimental Treatments for Myasthenia Gravis
Efgartigimod (ARGX-113) is designed to work by decreasing the number of circulating autoantibodies in autoimmune diseases such as MG. It is currently under FDA review for the treatment of generalized MG.
Firdapse (amifampridine) is being developed to treat muscle weakness in a rare type of MG called MuSK-MG. It is currently in Phase 3 trials in these patients.
Rituximab is designed to target a protein called CD-20 that is present in B-cells, which are harmful in MG. It is currently in Phase 3 trials.
Rozanolixizumab (UCB7665) is an investigational humanized monoclonal immunoglobulin G antibody. It is currently in Phase 3 trials for generalized MG.
Subcutaneous immunoglobulin, a new formulation of immunoglobulin, is given as an under-the-skin injection using a portable infusion pump. It is under investigation for MG treatment in Phase 3 trials.
Zilucoplan is a small, synthetic molecule that is designed to bind and inhibit portions of the immune system called the complement system. It is being tested in Phase 3 trials for generalized MG.
Batoclimab is a fully human monoclonal antibody being investigated for the treatment of autoimmune diseases such as MG. It is currently being tested in Phase 2 trials.
CFZ533 is designed to blocs immune responses that generate the antibodies responsible for causing muscle weakness. It is currently being tested in Phase 2 trials in moderate to severe MG.
DAS-MG (GTP-004) is an investigational medication being developed to treat muscle weakness associated with myasthenia gravis. It is currently in Phase 2 trials.
Myasterix (CV-MG01) is an investigational therapeutic vaccine intended to alleviate the symptoms of myasthenia gravis. It was most recently tested in a Phase 1 trial. A Phase 2/3 trial was planned but was withdrawn due to issues with recruitment.